Eisai Co., Ltd. and Biogen Inc. announced that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union… read more.
Each year, numerous patients worldwide require surgical interventions that could benefit from the precision and safety offered by surgical robots. The standard approach for complex surgeries often involves… read more.
Millions worldwide suffer from UV-induced skin damage, photoaging, and skin cancer annually. Current sunscreen efficacy testing relies on minimal erythema dose (MED) and minimal persistent pigment dose (MPPD);… read more.
Biogen Inc. anounced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMB® (lecanemab) will include 48-month results… read more.
Kite, a Gilead Company announced results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, open-label Phase 1/II study evaluating its chimeric antigen receptor (CAR) T-cell therapy… read more.
What if we could prevent people from developing obesity? The World Obesity Federation expects more than half the global population to develop overweight or obesity by 2035. However,… read more.
Wearable healthcare devices, such as glucose monitors and heart monitors, are popular due to their ability to gather real-time data that supports users’ health and safety. However, despite… read more.
NICE is unable to make a recommendation on tislelizumab (Tevimbra) in combination for untreated advanced non-small-cell lung cancer in adults. This is because the company did not provide… read more.
In an opinion piece published July 16 in the open-access journal PLOS Climate, Jeremy Jacobs of Vanderbilt University and Shazia Khan of Yale School of Medicine draw attention to the… read more.
Anti-obesity medications can significantly raise testosterone levels and improve health outcomes for men with obesity or type 2 diabetes, according to a new study being presented Monday at… read more.
NICE (UK): 1.1 Elafibranor is recommended, within its marketing authorisation, as an option for treating primary biliary cholangitis in adults, when used: i) with ursodeoxycholic acid (UDCA), if… read more.
Researchers at the University of Pittsburgh have identified a new way of predicting whether a kidney donor and recipient are a good match for transplantation. The findings, published today in Science… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
